% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • t57776 t57776 Apr 25, 2007 8:24 AM Flag

    morningstar..vrtx 1 of 5 to buy

    Vertex Pharmaceuticals (NasdaqGS:VRTX - News)
    Although this firm has several products in development--as well as a history of generating successful HIV therapeutics--all eyes are focused on the potential of telaprevir (VX-950) to treat patients with hepatitis C. The drug candidate has shown impressive efficacy to date, and while shares fallen from their peaks due to concerns over the drug's side effects, we think its efficacy and market position outweigh any safety problems that have arisen to date. As I discuss in the valuation section of my Analyst Report, I've assigned VX-950 a 60% probability of approval in 2009, and "we still believe that the drug will garner 30% of hepatitis C drug sales by 2015, and that the global market could be larger than $10 billion by that time."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
83.23+3.52(+4.42%)Feb 12 4:00 PMEST